Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups

Bibliographic Details
Main Author: Ribeiro Melki, Caio
Publication Date: 2022
Other Authors: Ribeiro e Fernandes, João Lucas, Soares Lima, Agnaldo
Format: Article
Language: eng
por
spa
Source: Brazilian Journal of Transplantation
Download full: https://bjt.emnuvens.com.br/revista/article/view/454
Summary: The modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12  months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24
id ABTO_c2730225d162c9cf1fd9dbd14f8b1ee5
oai_identifier_str oai:ojs3.emnuvens.com.br:article/454
network_acronym_str ABTO
network_name_str Brazilian Journal of Transplantation
repository_id_str
spelling Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic GroupsMeld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic GroupsCritério Meld na Fila de Transplantes: Impacto na Mortalidade Geral e por Grupos DiagnósticosTransplante de ÓrgãosTransplante de FígadoFígadoOrgan TransplantationLiver TransplantationLiverTransplante de ÓrganosTransplante de HígadoHígadoThe modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12  months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24La modificación de la ubicación de injertos hepáticos para selección por el criterio de gravedad basado en el model for end-stage liver disease (Meld) aún no fue debidamente analizada en Brasil con respecto a la distribución de las indicaciones al transplante y a la mortalidad entre los pacientes inscritos. En un contexto de baja donación y captación de órganos, esta evaluación es relevante. Objetivo: Comparar la mortalidad en la lista de espera de transplante hepático en Brasil antes y después de la adopción del score Meld como criterio de ubicación en la fila: general, por grupo diagnóstico y por rango de Meld a la inscripción. Métodos: Fueron estudiados, retrospectivamente, 899 pacientes (medianas de edad=52,8 años, índice de masa corpórea=25,2 y Meld=18) divididos en los períodos pre (n=320, 35,6%) y post-Meld (n=579, 64,4%) y en grupos: 1 (n=480, 53,4%): cirrosis etanólica, criptogénica y autoinmune; 2 (n=80, 8,9%): enfermedades biliares; 3 (n=93, 10,3%): enfermedades metabólicas y otros; y 4 (n=246, 27,4%): cirrosis postviral B y C. Puntuación especial fue atribuida al 19,5% de los pacientes, de acuerdo con criterios de la legislación. La muestra fue dividida también por rangos de Meld a la inscripción (<18; 18-24; y >24). Las mortalidades de la lista de espera de los grupos pre y post-Meld fueron comparadas en la muestra total, en cada grupo diagnóstico y en cada rango de Meld. Resultados: La incidencia de indicaciones al transplante fue diferente en las eras pre y post-Meld (p=0,049), aumentando en el grupo 3 (de 8,1 para 11,6%) y reduciéndose en el grupo 4 (de 32,5 para 24,5%). De los inscritos, 32,9% fallecieron antes del transplante. El Meld promedio aumentó de 16 para 20 (p<0,001), y el tiempo promedio entre la inscripción y el desenlace (transplante o fallecimiento) disminuyó de 102 días para 58 (p=0,028). La mortalidad en la lista de espera cayó de 105,7% (pacientes-año) para 54,9% en el grupo post-Meld (p=0,001). En el grupo 1 hubo una reducción de 104,2% (pacientes-año) para 51,1% (p=0,034), y en el grupo 2 la proporción cayó de 160,3% (pacientes-año) para 52% (p=0,019). Ya en los grupos 3 y 4 no hubo variación estadísticamente significativa. En el rango de Meld 1 (<18), la mortalidad varió de 87,2% por paciente-año a 24,1% por paciente-año (p=0,005). En el rango 2 (18-24), varió de 109,8 a 72,4% por paciente-año (p=0,019). En el rango de Meld>24, no hubo cambio significativo en la mortalidad en la lista de espera. Por fin, la sobrevida en uno, tres y 12 meses después del transplante no varió significativamente entre la era preMeld y post-Meld. Conclusión: Comparándose los grupos pre y post-Meld, los pacientes fueron inscritos cuando estaban más graves, y hubo reducción del tiempo promedio de evolución en la lista para el desenlace y disminución de la mortalidad en la lista de espera sin modificación de la sobrevida postransplante. Los grupos diagnósticos 1 y 2 fueron beneficiados. Además de esto, la disminución de la mortalidad en la lista de espera fue observada entre los pacientes con Meld<24 en el momento de la inscripción. Esta reducción no fue observada en el grupo de pacientes con Meld>24.A modificação da alocação de enxertos hepáticos para seleção pelo critério de gravidade baseado no model for end-stage liver disease (Meld) ainda não foi devidamente analisada no Brasil quanto à distribuição das indicações ao transplante e à mortalidade entre os pacientes inscritos. Em um contexto de baixa doação e captação de órgãos, essa avaliação é relevante. Objetivo: Comparar a mortalidade na lista de espera de transplante hepático no Brasil antes e depois da adoção do escore Meld como critério de alocação na fila: geral, por grupo diagnóstico e por faixa de Meld à inscrição. Métodos: Foram estudados, retrospectivamente, 899 pacientes (medianas de idade=52,8 anos, índice de massa corpórea=25,2 e Meld=18) divididos nos períodos pré (n=320, 35,6%) e pós-Meld (n=579, 64,4%) e em grupos: 1 (n=480, 53,4%): cirrose etanólica, criptogênica e autoimune; 2 (n=80, 8,9%): doenças biliares; 3 (n=93, 10,3%): doenças metabólicas e outros; e 4 (n=246, 27,4%): cirroses pós-viral B e C. Pontuação especial foi atribuída a 19,5% dos pacientes, de acordo com critérios da legislação. A amostra foi dividida também por faixas de Meld à inscrição (<18; 18-24; e >24). As mortalidades da lista de espera dos grupos pré e pós-Meld foram comparadas na amostra total, em cada grupo diagnóstico e em cada faixa de Meld. Resultados: A incidência de indicações ao transplante foi diferente nas eras pré e pós-Meld (p=0,049), aumentando no grupo 3 (de 8,1 para 11,6%) e reduzindo-se no grupo 4 (de 32,5 para 24,5%). Dos inscritos, 32,9% faleceram antes do transplante. O Meld médio aumentou de 16 para 20 (p<0,001), e o tempo médio entre a inscrição e o desfecho (transplante ou óbito) diminuiu de 102 dias para 58 (p=0,028). A mortalidade na lista de espera caiu de 105,7% (pacientes-ano) para 54,9% no grupo pósMeld (p=0,001). No grupo 1 houve redução de 104,2% (pacientes-ano) para 51,1% (p=0,034), e no grupo 2 a proporção caiu de 160,3% (pacientes-ano) para 52% (p=0,019). Já nos grupos 3 e 4 não houve variação estatisticamente significativa. Na faixa de Meld 1 (<18), a mortalidade variou de 87,2% por paciente-ano a 24,1% por paciente-ano (p=0,005). Na faixa 2 (18-24), variou de 109,8 a 72,4% por paciente-ano (p=0,019). Na faixa de Meld>24, não houve mudança significativa na mortalidade na lista de espera. Por fim, a sobrevida em um, três e 12 meses após o transplante não variou significativamente entre a era pré-Meld e pós-Meld. Conclusão: Comparando-se os grupos pré e pós-Meld, os pacientes foram inscritos quando estavam mais graves, e houve redução do tempo médio de evolução na lista para o desfecho e diminuição da mortalidade na lista de espera sem alteração da sobrevida pós-transplante. Os grupos diagnósticos 1 e 2 foram beneficiados. Além disso, a diminuição da mortalidade na lista de espera foi observada entre os pacientes com Meld<24 no momento da inscrição. Essa redução não foi observada no grupo de pacientes com Meld>24.Associação Brasileira de Transplante de Órgãos (ABTO)2022-06-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfhttps://bjt.emnuvens.com.br/revista/article/view/454Brazilian Journal of Transplantation; Vol. 25 No. 2 (2022)Brazilian Journal of Transplantation; v. 25 n. 2 (2022)2764-1589reponame:Brazilian Journal of Transplantationinstname:Associação Brasileira de Transplante de Órgãos (ABTO)instacron:ABTOengporspahttps://bjt.emnuvens.com.br/revista/article/view/454/458https://bjt.emnuvens.com.br/revista/article/view/454/459https://bjt.emnuvens.com.br/revista/article/view/454/460Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Limainfo:eu-repo/semantics/openAccessRibeiro Melki, CaioRibeiro e Fernandes, João LucasSoares Lima, Agnaldo2022-07-21T10:49:59Zoai:ojs3.emnuvens.com.br:article/454Revistahttps://bjt.emnuvens.com.br/revistaONGhttps://bjt.emnuvens.com.br/revista/oaibjt@abto.org.brhttps://doi.org/10.53855/2764-15892764-1589opendoar:2022-07-21T10:49:59Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)false
dc.title.none.fl_str_mv Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
Critério Meld na Fila de Transplantes: Impacto na Mortalidade Geral e por Grupos Diagnósticos
title Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
spellingShingle Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
Ribeiro Melki, Caio
Transplante de Órgãos
Transplante de Fígado
Fígado
Organ Transplantation
Liver Transplantation
Liver
Transplante de Órganos
Transplante de Hígado
Hígado
title_short Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
title_full Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
title_fullStr Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
title_full_unstemmed Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
title_sort Meld Criteria in the Transplant Waiting List: Impact on Mortality Overall and by Diagnostic Groups
author Ribeiro Melki, Caio
author_facet Ribeiro Melki, Caio
Ribeiro e Fernandes, João Lucas
Soares Lima, Agnaldo
author_role author
author2 Ribeiro e Fernandes, João Lucas
Soares Lima, Agnaldo
author2_role author
author
dc.contributor.author.fl_str_mv Ribeiro Melki, Caio
Ribeiro e Fernandes, João Lucas
Soares Lima, Agnaldo
dc.subject.por.fl_str_mv Transplante de Órgãos
Transplante de Fígado
Fígado
Organ Transplantation
Liver Transplantation
Liver
Transplante de Órganos
Transplante de Hígado
Hígado
topic Transplante de Órgãos
Transplante de Fígado
Fígado
Organ Transplantation
Liver Transplantation
Liver
Transplante de Órganos
Transplante de Hígado
Hígado
description The modification of liver graft allocation for selection by severity criteria based on the Model for End-Stage Liver Disease (Meld) has not yet been properly analyzed in Brazil regarding the distribution of indications for transplant and mortality among enrolled patients. In a context of low organ donation and procurement, this assessment is relevant. Objective: To compare mortality on the liver transplant waiting list in Brazil before and after the adoption of Meld score as a criterion for allocation on the waiting list: overall, by diagnostic group, and by Meld range at enrollment. Methods: We retrospectively studied 899 patients (median age = 52.8 years, body mass index, BMI = 25.2 and Meld = 18) divided into the pre- (n = 320, 35.6%) and post-Meld (n = 579, 64.4%) periods and into groups: 1 (n = 480, 53.4%): ethanolic, cryptogenic and autoimmune cirrhosis; 2 (n = 80, 8.9%): biliary diseases; 3 (n = 93, 10.3%): metabolic and other diseases; and 4 (n = 246, 27.4%): post-viral B and C cirrhosis. Special scoring was assigned to 19.5% of patients, according to legislation criteria. The sample was also divided by Meld ranges at enrollment (< 18; 18–24; and > 24). Waitlist mortalities of the pre- and post-Meld groups were compared in the total sample, in each diagnostic group, and in each Meld range. Results: The incidence of referrals to transplantation was different in the pre- and post-Meld eras (p = 0.049), increasing in group 3 (from 8.1 to 11.6%) and decreasing in group 4 (from 32.5 to 24.5%). Of the enrollees, 32.9% died before transplantation. Mean Meld increased from 16 to 20 (p < 0.001), and mean time between enrollment and outcome (transplant or death) decreased from 102 days to 58 (p = 0.028). Waiting list mortality dropped from 105.7% (patient-years) to 54.9% in the post-Meld group (p = 0.001). There was a reduction from 104.2% (patientyears) to 51.1% (p = 0.034) in group 1, and the proportion fell from 160.3% (patient-years) to 52% (p = 0.019) in group 2. On the other hand, there was no statistically significant variation in the groups 3 and 4. In Meld range 1 (< 18), mortality ranged from 87.2% per patient-year to 24.1% per patientyear (p = 0.005). In Meld range 2 (18–24), it ranged from 109.8 to 72.4% per patient-year (p = 0.019). In the Meld > 24 range, there was no significant change in waitlist mortality. Finally, survival at 1, 3 and 12  months after transplantation did not vary significantly between the pre-Meld and postMeld era. Conclusion: Comparing the pre- and post-Meld groups, patients were enrolled when they were most severely ill, and there was a reduction in mean time on the list for the outcome and a decrease in waiting list mortality with no change in post-transplant survival. Diagnosis groups 1 and 2 have benefited. In addition, the decrease in waiting list mortality was observed among patients with Meld < 24 at the time of enrollment. This reduction was not observed in the group of patients with Meld > 24
publishDate 2022
dc.date.none.fl_str_mv 2022-06-15
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/454
url https://bjt.emnuvens.com.br/revista/article/view/454
dc.language.iso.fl_str_mv eng
por
spa
language eng
por
spa
dc.relation.none.fl_str_mv https://bjt.emnuvens.com.br/revista/article/view/454/458
https://bjt.emnuvens.com.br/revista/article/view/454/459
https://bjt.emnuvens.com.br/revista/article/view/454/460
dc.rights.driver.fl_str_mv Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Lima
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Caio Ribeiro Melki, João Lucas Ribeiro e Fernandes, Agnaldo Soares Lima
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
publisher.none.fl_str_mv Associação Brasileira de Transplante de Órgãos (ABTO)
dc.source.none.fl_str_mv Brazilian Journal of Transplantation; Vol. 25 No. 2 (2022)
Brazilian Journal of Transplantation; v. 25 n. 2 (2022)
2764-1589
reponame:Brazilian Journal of Transplantation
instname:Associação Brasileira de Transplante de Órgãos (ABTO)
instacron:ABTO
instname_str Associação Brasileira de Transplante de Órgãos (ABTO)
instacron_str ABTO
institution ABTO
reponame_str Brazilian Journal of Transplantation
collection Brazilian Journal of Transplantation
repository.name.fl_str_mv Brazilian Journal of Transplantation - Associação Brasileira de Transplante de Órgãos (ABTO)
repository.mail.fl_str_mv bjt@abto.org.br
_version_ 1836111235144220672